REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Natural metabolites targeting macrophage polarization for non-small cell lung cancer therapy: A review of mechanisms and applications based on chemical classification
- YZ
Yuxuan Zhang
- LL
Lu Liu
- HY
Hongyan Yan
- XL
Xudong Lei
- HY
Hua Yang
Sun Yet-sen University Cancer Center Gansu Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Non-small cell lung cancer (NSCLC) accounts for roughly 85% of lung cancer cases and is a leading cause of cancer-related death worldwide. Reprogramming tumor-associated macrophages (TAMs) from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype has emerged as a promising therapeutic strategy. This review examines naturally occurring metabolites that modulate TAM polarization in NSCLC, organized into eight chemical classes: flavonoids, alkaloids, terpenoids, polysaccharides, saponins, stilbenoids, lignans, and phenolic acids. A recurring finding is that these compounds converge on shared signaling pathways, particularly PI3K/Akt/mTOR, NF-κB, and STAT family members, while each class also displays distinct mechanistic tendencies. Flavonoids couple redox modulation with immune effects. Alkaloids engage multiple targets but carry dose-dependent toxicity. Terpenoids show strong tumor microenvironment penetration and synergy with immune checkpoint inhibitors. Polysaccharides act through membrane receptors such as Toll-like receptors and Dectin-1. Saponins largely center on AMPK signaling. The remaining classes, though supported by fewer studies, point to MDSC regulation and context-dependent effects. Multi-component plant extracts and traditional Chinese medicine formulas also influence TAM polarization and have reached adjuvant clinical use. Delivery platforms such as nanoparticles, hydrogels, and exosomes are being developed to address poor bioavailability. Translation remains limited by a lack of trials with TAM-specific endpoints, an oversimplified M1/M2 framework, and the need for standardized pharmacokinetic and targeting assessments. Future progress will require biopsy-based TAM phenotyping, biomarker-driven patient stratification, and delivery systems matched to metabolite properties.
Summary
Keywords
Macrophage polarization, natural metabolites, Non-small cell lung cancer, Tumor Microenvironment, Tumor-associated macrophages
Received
15 April 2026
Accepted
07 August 2026
Copyright
© 2026 Zhang, Liu, Yan, Lei and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hua Yang
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.